Ascletis Entered into an Exclusive WW License Agreement with Suzhou Alphamab for ASC22 (envafolimab) to Treat Hepatitis B and Other Viral Diseases
Shots: Suzhou Alphamab to receive up front & will be eligible to receive development, regulatory & commercial milestones along with royalties & will manufacture ASC22 for clinical trials & commercialization of viral indications Ascletis holds an exclusive & global license to develop & commercialize ASC22 for all viral diseases including Hepatitis B outside Greater China […]